TP53 regulates human AlkB homologue 2 expression in glioma resistance to Photofrin-mediated photodynamic therapy

SY Lee1, SK Luk1, CP Chuang1, SP Yip1, SST To*,1 and YMB Yung1

1Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong Special Administrative Region, China

BACKGROUND: Photodynamic therapy (PDT) is a promising adjuvant therapy in cancer treatment. However, cancers resistant to PDT, mediated through the efflux of photosensitisers by means of P-glycoprotein or ATP-binding cassette transporter proteins, have been reported. The DNA repair has also been suggested to be responsible for PDT resistance, but little is known about the repair pathways and mechanisms involved. Therefore, this study aimed to investigate the possible function of six major DNA repair mechanisms in glioma cells resistant to Photofrin-mediated PDT (Ph-PDT).

METHODS: The U87 glioma cells relatively resistant to Ph-PDT were obtained by recovering the viable cells 3 h after PDT treatment. The mRNA and protein expression levels of DNA repair genes were evaluated by quantitative real-time reverse transcription-polymerase chain reaction and western blotting, respectively. Small-interfering RNA and chromatin-immunoprecipitation assays were used to further examine the relationship between AlkB, an alkylation repair homologue 2 (Escherichia coli) (ALKBH2) and Ph-PDT responsiveness, and transcription factors involved in ALKBH2 transcription.

RESULTS: The ALKBH2 of DNA damage reversal was significantly increased at both mRNA and protein levels from 30 min to 48 h post-treatment with Ph-PDT. Conversely, down-regulating ALKBH2 expression enhances Ph-PDT efficiency. Furthermore, our data clearly show for the first time that tumour protein (TP53) is directly involved by binding to the promoter of ALKBH2 in mediating Ph-PDT resistance.

CONCLUSION: The DNA damage reversal mechanisms may have important functions in Ph-PDT resistance through the activation of ALKBH2 by TP53.

British Journal of Cancer (2010) 103, 362 – 369. doi:10.1038/sj.bjc.6605797 www.bjcancer.com

Keywords: TP53; ALKBH2; DNA repair; Photofrin; photodynamic therapy

Glioblastoma multiforme is one of the most common tumours affecting the brain and notoriously difficult to cure. It is because glioma cells are particularly resistant to therapy and coupled with the problem of the blood–brain barrier, and the susceptibility of healthy brain tissue to damage during treatment, new adjuvant therapies are clearly needed to tackle this treatment-resistant tumour (Gerstner and Fine, 2007).

Photodynamic therapy (PDT) is an emerging adjuvant therapy used in the treatment of different tumours (O’Connor et al, 2009). The PDT has several advantages over traditional treatment regimens. Compared with surgery and radiotherapy, PDT causes less severe long-term morbidity with comparable treatment outcomes (Nyst et al, 2009). It can also be the choice of re-treatment in cases of recurrence and incomplete tumour responses after standard therapies and/or PDT as PDT does not compromise re-treatment effectiveness (Hornung et al, 1998).

The PDT uses the excitation of photosensitisers in tumour cells by light to interact with the oxygen in tissues, thus reactive oxygen species are produced to kill the tumour cells through apoptosis or necrosis (Pervaiz, 2001). Photofrin is the most commonly used photosensitiser, and Photofrin-mediated PDT (Ph-PDT) has already been approved for the treatment of different solid tumours by the US Food and Drug Administration (Biel, 2006). Clinical trials using Photofrin to treat gliomas are being carried out, but reports on glioma cell resistance to Ph-PDT in vitro or in vivo are emerging (Adams et al, 1999; Ferrario et al, 2007). This situation is also seen in head and neck dysplasia or cancer patients in which some of them failed to respond, or only partially responded to Ph-PDT (Styli et al, 2004; Rigual et al, 2009). The underlying cellular mechanisms leading to failure to respond to Ph-PDT are not fully understood. Several proteins and signalling pathways, such as activation of anti-apoptotic proteins, cellular antioxidant defence mechanisms and efflux of photosensitisers by means of P-glycoprotein or ATP-binding cassette transporter proteins have been shown to have significant functions in cellular resistance to Ph-PDT (Saczko et al, 2007a; Usuda et al, 2008, 2010; Zheng et al, 2008). The interactions of these different pathways and proteins may enhance tumour cell proliferation and differentiation, promote invasion and prevent apoptosis, leading to the decreased cytotoxicity of Ph-PDT.

The DNA repair has been shown to reduce cell death caused by different cancer therapies, including radiotherapy and chemotherapy using a platinum agent (Frosina, 2009; Fukushima et al, 2009). The Ph-PDT has also been reported to induce significant
DNA damage and repair in different cell types (Woods et al., 2004; Saczko et al., 2008). Although different mechanisms have been suggested to explain the causes of resistance in Ph-PDT, the function of DNA repair mechanisms has not been fully investigated. Therefore, we carried out a series of experiments to investigate the DNA repair mechanism(s) that may be responsible for the survival of glioma cells after Ph-PDT. Specific genes representative of the main DNA repair pathways in human beings were examined. The six specific genes are (1) AlkB, alkylation repair homologue 2 (Escherichia coli) (ALKBH2) of direct DNA damage reversal; (2) APEX nuclease (multifunctional DNA repair enzyme) 1 (APEX1) of base excision repair (BER), which removes small base lesions; (3) X-ray repair complementing defective repair in Chinese hamster cells 1 (XRCC1) of short-patch BER, which is responsible for repairing single base damage; (4) excision repair cross-complementing rodent repair deficiency, complementation group 5 (ERCC5) of nucleotide excision repair (NER) that repairs bulky, helix-distorting lesions NER; (5) RAD52 homologue (Saccharomyces cerevisiae) (RAD52) of double-strand break repair and (6) REV1 homologue (S. cerevisiae) (REV1) of trans-lesion synthesis, which is a DNA damage tolerance machinery (Christmann et al., 2003).

In this study, viable glioma cells recovered 3 h after Ph-PDT were considered as relatively resistant/less responsive to Ph-PDT. The gene ALKBH2, involved in DNA damage reversal, was significantly expressed in these cells for at least 24 h after Ph-PDT. Knockdown of ALKBH2 intensified the cytotoxic effect of Photofrin, which implies that it confers resistance to Ph-PDT. We also showed both mRNA and protein levels of ALKBH2 were up-regulated. This up-regulation was due to the binding of the transcription factor tumour protein (TP53) to one of the predicted promoter regions of ALKBH2, a finding that has not been reported before.

MATERIALS AND METHODS

Cell culture

The human glioblastoma U87 cell line was obtained from American Type Culture Collection (Rockville, MD, USA). The cells were maintained in Minimum Essential Medium Alpha (Invitrogen, Carlsbad, CA, USA) supplemented with 10% foetal bovine serum (complete medium) and were grown in a humidified atmosphere at 37 °C and 5% CO2.

Photosensitisers and photodynamic treatment

Photofrin was a generous gift from Axcan Pharma (Quebec, Canada). Stock solution (2.5 mg ml⁻¹) was prepared in 5% dextrose and kept at −20 °C until use. Cells (2 × 10⁵) were seeded onto 60 mm culture dishes in complete medium and incubated overnight. Cells were then incubated in serum-free medium containing 1 µg ml⁻¹ Photofrin for at least 18 h to achieve maximal uptake before being illuminated (Ph-PDT) (Jiang et al., 2005; Dysart and Patterson, 2005; An et al., 2006). Light irradiation of cells was carried out using a quartz-halogen lamp coupled with a 500 nm long-pass filter. The energy fluence rate was 33.5 mW cm⁻² at a wavelength of 630 nm. The following controls were also included in all experiments: cell cultures without Photofrin and light irradiation (no treatment controls); without Photofrin, but illuminated (light controls, LCs) and with Photofrin, but not illuminated (dark controls, DCs). Three hours after light irradiation, the cells were used directly for cell survival and alkaline comet assays (for examining DNA damage) or allowed to recover in complete medium for various times before being analysed by (i) chromatin immunoprecipitation (ChIP), (ii) western blotting, (iii) real-time quantitative reverse transcription-polymerase chain reaction (RT–PCR) and (iv) alkaline comet assay (for examining DNA repair).

Cell survival assay

Cell survival was determined using the trypan-blue exclusion method. Cells were diluted 1:9 in 500 µl phosphate-buffered saline (PBS) and stained with trypan blue. They were then analysed using an automated Vi-CELL cell viability analyser (Beckman Coulter, Brea, CA, USA), which has linearity approximately from 5 × 10⁴ to > 1 × 10⁵ cells ml⁻¹ (Szabo et al., 2004). The number of viable cells in 50 images was counted and three replicates were performed on each sample.

Alkaline comet assay

The assay was performed according to an earlier described procedure (Collins et al., 1997). In brief, 4 × 10⁴ cells were mixed with 60 µl of 1% low melting point agarose in PBS (37 °C) and embedded on an agarose pre-treated standard microscope slide. The slides were then immersed in lysis buffer for 1 h to denature the cellular proteins and then transferred to the alkaline electrophoresis buffer and incubated for 30 min at 4 °C in the dark for DNA unwinding. Electrophoresis was then conducted for 30 min at 25 V and 300 mA. Slides were neutralised with three changes of 0.4 M Tris–HCl buffer, pH 7.5, for 5 min each and stained with 30 µl ethidium bromide (20 µg ml⁻¹). Individual comets were viewed at a final magnification of ×400 using a fluorescence microscope (Eclipse E600, Nikon, Tokyo, Japan) equipped with 590 nm long-pass emission filter. Comets from two slides of each sample were analysed using the Komet 5.5 software (Kinetic imaging, Liverpool, UK) and 150 individual comets were counted.

Real-time quantitative RT–PCR

Total RNA was isolated using PureLink Micro-to-Midi Total RNA Purification kit (Invitrogen), and reverse transcribed using RevertAid First Strand cDNA Synthesis kit (Fermentas, Ontario, Canada) with oligo-dT' primers according to the manufacturers’ protocols. To analyse the relative gene expression, cDNA was then subjected to TaqMan-based real-time quantitative PCR in a 7500 Real-Time PCR system (Applied Biosystems, Foster City, CA, USA). Briefly, 7.5 ng of cDNA were added to 20 µl of PCR mix containing 1 × Universal PCR Master Mix and 1 µl validated TaqMan gene expression assay mix (Applied Biosystems) for each gene shown in Table 1. The amplification was carried out as follows: 1 cycle for denaturation (95 °C per 10 min) followed by 40 cycles for two-stage PCR (95 °C per 15 s and 60 °C per 1 min). Fluorescence signals were measured continuously during the repetitive cycles. The relative changes in gene expression were calculated based on the 2−ΔΔCt method (Livak and Schmittgen, 2001).

Western blotting

Cells were collected, washed in ice-cold PBS and lysed in WCE buffer (20 mM HEPES, 1 mM EDTA, 1 mM EGTA, 0.2 M NaCl, 0.5% Triton X-100, 10% glycerol and complete mini protease inhibitor cocktail tablet (Roche, Branchburg, NJ, USA)). The lysates were boiled in SDS sample buffer (62.5 mM Tris–HCl (pH 6.8), 1% β-mercaptoethanol, 10% glycerol, 1% SDS and 0.001% bromophenol blue) and separated by 15% SDS–PAGE. The separated proteins were then blotted onto PVDF membranes (Amersham Biosciences, Uppsala, Sweden) and blocked with 5% non-fat milk or 5% bovine serum albumin (for Phospho-p53 antibody) in Tris-buffered saline (pH 7.4) containing 0.1% Tween 20 for 1 h at room temperature. To examine different protein expression, the membranes were probed with antibodies against ALKBH2 (1:1000 dilution, Abcam,
Table 1 The validated TaqMan gene expression assays

| Primers | Assay ID | Interrogated sequence | Exon boundary | Assay location | Amplicon length (bp) |
|---------|----------|-----------------------|---------------|---------------|---------------------|
| (1) ALKBH2 | Hs00419572_m1 | NM_001001655.1 | 2–3 | 478 | 86 |
| (2) REV1 | Hs00249411_m1 | NM_001037872.1 | 2–3 | 268 | 63 |
| (3) RADS2 | Hs00172536_m1 | NM_134424.2 | 2–3 | 197 | 65 |
| (4) APEX1 | Hs00172396_m1 | NM_080648.1 | 3–4 | 510 | 81 |
| (5) XRCC1 | Hs00959834_m1 | NM_006297.2 | 4–5 | 536 | 75 |
| (6) ERCC5 | Hs00164842_m1 | NM_000123.2 | 14–15 | 3407 | 118 |

Adapted and modified from http://www.appliedbiosystems.com.hk/

Table 2 The primers used in conventional and real-time quantitative PCR for ChIP analysis

| Primers | Sequences (5' to 3') | Positions | Applications |
|---------|----------------------|-----------|--------------|
| (1) p53_F1 | TGCTCCACCTCTGACAATA | −257 to −238 | Used in conventional PCR and real-time PCR of position 1 p53-binding site. |
| (2) p53_R2 | GCCACTGTCGAGAATCAC | −138 to −155 | Used in real-time PCR of position 1 p53-binding site only. |
| (3) p53_F2 | CACGCCGTGATTCTGAGA | −143 to −160 | Used in real-time PCR of position 2 p53-binding site only. |
| (4) p53_R1 | AACGGAAGGAAAATTCTGTAT | +147 to +125 | Used in conventional PCR and real-time PCR of position 2 p53-binding site. |

Abbreviations: ChIP = chromatin immunoprecipitation; PCR = polymerase chain reaction.

Cambridge, UK), REV1 (1:500 dilution, Abcam), NPM/B23 (1:1000 dilution), p53 (1:200 dilution, Santa Cruz Biotechnology, Santa Cruz, CA, USA), Phospho-p53 (Ser-15) (1:1000 dilution, Cell Signaling Technology, Beverly, MA, USA) and β-actin (1:2000 dilution, Santa Cruz Biotechnology). Corresponding horseradish peroxidase-labelled anti-rabbit and anti-mouse antibodies were used as secondary antibodies (Cell Signaling Technology). The final complexes were visualised by enhanced chemiluminescence autoradiography (Perkin Elmer, Cambridge, MA, USA).

Small-interfering RNA transfection

Fifty per cent confluent density of U87 glioma cells (1 × 10^5) were seeded onto 35 mm dishes in complete medium and incubated overnight. Small-interfering RNA (siRNA) oligomers and Lipofectamine 2000 transfection reagent (100 pmol and 1:50 dilution, Invitrogen) were mixed with serum-free medium, incubated and added to each dish. In mock controls, the negative control RNA was used instead of siRNA to act as a control. Cells incubated with Lipofectamine alone were used as reagent control. After 6 h of incubation, the cells were recovered in complete medium for 16 h. They were then subjected to Ph-PDT treatment as described above. Three hours after light irradiation, cells were analysed by real-time quantitative RT–PCR, western blotting and cell survival assay.

Chromatin immunoprecipitation

The U87 glioma cells were allowed to recover for 6 h after Ph-PDT. They were then cross-linked by formaldehyde (1% final concentration) at room temperature for 10 min. The fixation was quenched by the addition of glycine at a final concentration of 0.125 M. The cells were washed with cold PBS containing protease inhibitors (Roche) and collected by scraping. The ChIP was performed using the MAGnify chromatin-immunoprecipitation system (Invitrogen) according to the manufacturer’s protocol. Briefly, the cells were lysed and chromatin was released from the nuclei. Chromatin was sheared to around 200 to 500 bp fragment sizes by sonication. The cross-linked protein–protein and protein–DNA fragments were immunoprecipitated by anti-TP53 or anti-IgG antibodies conjugated to Dynabeads Protein A/G. The cross-linking was reversed by heat treatment, and DNA associated with TP53 was isolated by DNA purification magnetic beads.

The isolated DNA was analysed by both conventional and real-time PCR.

PCR analysis for ChIP

The primers (Table 2) for conventional and SYBR green real-time quantitative PCR were designed from Homo sapiens chromosome 12 reference complement sequence (accession no: NC_000012.10) using the Oligo program version 6.57 (Molecular Biology Insights, Cascade, CO, USA). In conventional PCR, 5 μl of each DNA sample from ChIP assay were mixed with 25 μl of PCR master mix containing 1X GeneAmp PCR Gold Buffer, 0.2 mM of each dNTP, 2.5 mM MgCl₂, 0.3 μM of each primer and 0.5U AmpliTaq Gold DNA polymerase (Applied Biosystems). The amplification cycle was carried out as follows: 1 cycle for denaturation (95°C per 5 min) followed by 30 cycles of amplification (95°C per 15 s, 55°C per 1 min and 72°C per 1 min) and final extension of 10 min at 72°C. The PCR products were subjected to agarose gel electrophoresis for examination. In real-time quantitative PCR using SYBR green, 5 μl of each DNA sample were mixed with 25 μl of PCR mix containing Maxima SYBR Green/ROX qPCR Master Mix (Fermentas) and 0.3 μM of each primer. The amplification cycle used was as follows: 1 cycle for denaturation (95°C per 10 min) followed by 40 cycles for amplification (95°C per 15 s and 60°C per 1 min). Fluorescence signals were measured continuously during the repetitive cycles with an Applied Biosystems 7500 Real-Time PCR system. The relative changes in gene expression were calculated based on the 2^–ΔΔCt method.

Statistics

Data are presented as mean ± s.d. Statistical significance for differences was determined by paired t-test, one-way ANOVA with Tukey’s post-test and two-way ANOVA with Bonferroni’s post-test.

RESULTS

Photofrin-mediated photodynamic treatment causes DNA damage

The U87 glioma cells without Photofrin treatment were exposed to different light doses, namely control (CNT) at 0 J cm⁻², LC 1 at 0.8 J cm⁻² and LC 2 at 1.3 J cm⁻², respectively. The mean DNA
percentage in comet tails of LCs (\(\sim 2\%\)) was not significantly different from CNT (Figure 1). When cells were treated with Photofrin (1 \(\mu\)g/ml\(^{-1}\)) and exposed to different light doses (DC at 0 \(\text{J cm}^{-2}\), lethal dose (LD) 10 and 40 (LD 10 and LD 40), there was significant DNA damage as the mean DNA percentage in comet tails increased 3 h (black bars in Figure 1) after light irradiation (8.1% in DC, 13.9% in LD 10 and 33.2% in LD 40; all \(P<0.001\) when compared with that of CNT). Photofrin alone caused DNA damage and light activation caused further DNA damage in a light dose-dependent manner.

**Involvement of DNA repair in relatively resistant glioma cells after recovery from Ph-PDT**

To determine whether there was any DNA repair in the relatively resistant glioma cells that survived Ph-PDT, DNA damage was evaluated after the cells had been allowed to recover for 24 h. There was no significant change in the mean DNA percentage in comet tails of CNT and LCs. In contrast, the mean DNA percentage of DC (3.3%), LD 10 (10.3%) and LD 40 (20.3%) were reduced considerably when compared with those cells that had recovered for 3 h only (white bars compared with black bars in Figure 1).

**ALKBH2 expression increases significantly after recovery from Ph-PDT**

The involvement of the six selected DNA repair pathways were evaluated by determining the relative mRNA expression levels (\(\Delta\Delta C_{t}\)) of their target DNA repair genes in glioma cells, that is surviving cells after Ph-PDT, 48 h after treatment. Most of the target genes were expressed equally in both control and treated cells (Figure 2A). However, ALKBH2 and REV1 were significantly over-expressed in those LD 10 and LD 40 recovering cells by approximately 3- and 1.4-fold, respectively, when compared with the controls (\(P<0.01\)). Corresponding increased protein levels of ALKBH2 were observed (Figure 2B), but not in REV1 (data not shown). The kinetics of ALKBH2 gene expression was further investigated by quantitative RT–PCR.

**TP53 and ALKBH2 in glioma PDT resistance**

SY Lee et al

The mRNA level was evidently induced from 0.5 h and remained high at 12 h (Figure 2C). The corresponding ALKBH2 protein was also elevated in a time-dependent manner (Figure 2D). Up-regulation of ALKBH2 at the protein level, but not at the RNA level, was found in DC group. Increase in ALKBH2 translation in DC group may be due to the small amount of DNA damage induced by the dark toxicity of Photofrin (see Figure 1).

**Knockdown of ALKBH2 significantly increases the cytotoxicity of Ph-PDT**

Compared with the control cells (transfected with Lipofectamine alone or negative control RNA), siALKBH2 cells had much reduced ALKBH2 protein expression (Figure 3A). The sensitivity of these cells to Photofrin was more than those of the control cells, resulting in more cell deaths after light irradiation (Figure 3B). The sensitising effect was more evident with increasing light doses, with a cytotoxicity at \(\sim 8\%\) at low light dose (0.8 \(\text{J cm}^{-2}\)) and increased to \(\sim 25\%\) at high light dose (1.3 \(\text{J cm}^{-2}\)). The cytotoxicity levels did not reach the respective LD 10 and LD 40 levels because the uptake of Photofrin was reduced in the presence of Lipofectamine (data not shown).

**Ph-PDT increases the expression of TP53 transcription factor and its activated phosphorylated form – p-TP53**

To investigate the induction of ALKBH2 gene expression under Ph-PDT condition, transcription factor-binding sites on ALKBH2 were predicted and assessed. According to the Transcription Element Search System (TESS) web tool (http://www.cbil.upenn.edu/cgi-bin/tess/tess?RQ=WELCOME), TP3 is one of the potential-binding transcription factors. Its function in Ph-PDT was first examined by RT–PCR and western blotting. The mRNA and protein expression of TP3 in U87 glioma cells were shown to be increased 0.5 h after PDT (Figure 4A). The protein expression was maximal at 0.5 and 3.5 h. The level of p-TP53, which is associated with DNA repair mechanisms, was also shown to increase from 3.5 to 12.5 h in PDT-treated glioma cells.

**Increased TP53 binding on ALKBH2 after Ph-PDT treatment**

To show whether TP53 is involved directly, through binding as a transcription factor, in the transcription of ALKBH2 induced by Ph-PDT, the ChIP assay was used. Figure 4B clearly shows that TP53 binds to ALKBH2 gene, as there was a PCR product in the TP53-immunoprecipitated sample of Ph-PDT-treated cells. Two TP53-binding sites (approximately –190 bp and –14 bp; +1 is transcription start site) were predicted by TESS. Real-time PCR was used to determine the binding position of TP53 on ALKBH2 promoter sequence. Figure 4C confirms TP53 binding to ALKBH2 as well as indicating its binding location at –190 bp (4.5-fold increase), but not at the –14 bp region.

**DISCUSSION**

Numerous studies have shown that Ph-PDT induces significant DNA damage (Woods et al, 2004; Szczko et al, 2008). Different types of DNA damage may be seen, including double-strand breaks, single-strand breaks, DNA base oxidation and cross-links (Nowis et al, 2005). As DNA damage is not directly linked to the cell death caused by PDT, little research has been conducted to investigate the involvement of DNA repair in PDT. However, Penning et al (1994) showed that the inhibition of a DNA repair enzyme (poly(ADP-ribose)polymerase) activity and the formation of irreversible DNA damage were correlated to the killing effect of hematoporphyrin derivative PDT in a murine fibroblast cell line;
**Figure 2** Photofrin-mediated PDT induces DNA repair gene expression. (**A**) Quantitative real-time RT–PCR of DNA repair genes at 48 h after Photofrin-mediated PDT. ALKBH2 and REV1 were significantly expressed in LD10 and LD 40; DC is used as reference sample and CNT is used to examine the background expression levels of different DNA repair genes in U87 glioma cells. Data are expressed as mean ± s.d. and analysed using one-way ANOVA with Tukey’s multiple comparison post-test of three independent experiments (***P < 0.01). (**B**) Increased ALKBH2 protein levels in glioma cells at 48 h after Ph-PDT. (**C**) Quantitative real-time RT–PCR showed significant ALKBH2 gene expression at different time points after Photofrin-mediated PDT at LD 10. The mRNA level was significantly increased when compared with that of CNT and DC. Data are expressed as mean ± s.d. and analysed using two-way ANOVA with Bonferroni’s post-test of three independent experiments (*** represents the whole curve of LD 10 group is significant compared with both DC and CNT with P < 0.001 at 0.5, 3.5 and 12.5 h and P < 0.01 at 6.5 and 9.5 h). (**D**) Protein expression of ALKBH2 at different time points after Photofrin-mediated PDT treatment at LD 10.
note that Photofrin is purified form of hematoporphyrin derivative. They suggested that the involvement of DNA damage and repair in PDT is cell-type dependent. Another study by Gupta et al. (2003) illustrated that enhanced DNA repair lowered the micronuclei frequencies and thus increased the relative resistance to PDT. The DNA repair capacity is determined not only by cell type, but also the oxygen concentration and subcellular localisation of Photofrin. As glioma treatment using Ph-PDT is under clinical trial, the detailed DNA repair mechanism involved should be studied, so that the efficacy of Ph-PDT can be enhanced by preventing DNA repair-induced resistance.

On the basis of the knowledge gained from the studies mentioned above, our preliminary focus was to examine the participation of DNA damage and repair in a glioma cell line after Ph-PDT. Our results were consistent with other reports in that the amount of DNA damage is positively associated with PDT light dosage (Woods et al., 2004). The DNA damage is increased in Ph-PDT treatment groups (LD 10 and LD 40) when the PDT light
dose was increased (Figure 1). The DNA damage in treatment groups are significantly different from the glioma cells treated with light only (LCs) and with Photofrin only (DC). It is clear from the results presented here that light only will not cause significant DNA damage. In the DC, DNA was damaged to a lesser extent when compared with the PDT-treated groups. The DNA damage in the DC may be due to the low dose of light coming from ambient lighting that affected the cells during the course of the experiments. As Photofrin is not localised in the nucleus to cause DNA damage, the increase of DNA damage in PDT-treated groups may be explained by the impairment of the nuclear membrane after light irradiation (Moan et al, 1990; Saczko et al, 2007b). Consequently, sensitised reactive molecules, including photoproducts, can enter the nucleus and damage DNA (Evensen and Moan, 1982).

The DNA repair efficiency was less effective in the low light dose (LD 10) treatment group than that in the high light dose (LD 40) group. As the DNA repair capacity of the cells should be the same, the difference in the efficiency may be resulted from different DNA repair kinetics being activated by different light doses. Although DNA damage was also found in DCs, the damage was completely repaired after 24 h. This may be due to the small amounts of DNA damage present in the DC cells, but the participation of another DNA repair kinetics cannot be excluded. As our data indicate that DNA repair mechanisms are triggered in the relatively resistant U87 glioma cells after 48 h of recovery from Ph-PDT, we used real-time quantitative RT–PCR to determine which DNA repair gene(s) might be involved. The expression of the ALKBH2 gene of DNA damage reversal and, to a much lesser extent, the REV1 gene of translesion synthesis were found to be induced (Figure 2). The results indicate both DNA damage reversal and translesion synthesis mechanisms may have important functions in glioma cells resistant to Ph-PDT. The REV1 gene is involved in translesion synthesis, and allows damaged DNA to be tolerated by replicative bypass. When translesion synthesis is triggered, DNA replicates with mutations or errors and thus DNA damage-induced mutagenesis occurs (Prakash et al, 2005). As ALKBH2 is more significantly expressed in the relatively resistant glioma cells, we focused on the molecular process leading to induction of ALKBH2 expression during Ph-PDT and its contribution to PDT resistance.

The ALKBH2 gene is not significantly expressed in normal brain cells, but high levels are found in liver tissue and sexual organs (Duncan et al, 2002; Lee et al, 2005). It is responsible for repairing 1-methyladenine (1meA), 3-methylcytosine (3meC) and 1,N\(^2\)-ethenoadenine (\(\varepsilon\)A) on double-stranded DNA by oxidative demethylation (Lee et al, 2005; Ringvoll et al, 2008). Cetica et al (2009) showed that ALKBH2 is highly expressed in gliomas and suggested that this expression aberration has a part in tumour cell resistance to cancer treatments. We also found an up-regulation of ALKBH2 in glioma cells from 30 min to 48 h post-treatment with Ph-PDT. This observation may imply that the photosensitised reactive products in Ph-PDT produce 1meA, 3meC and/or \(\varepsilon\)A on DNA. Most DNA damage studies of Ph-PDT target DNA damage caused by oxidation. Here, we suggest that the photosensitised reactive products may also cause DNA methylation and lipid peroxidation to produce methylated DNA damage and etheno-adenine DNA lesions, respectively. Prolonged high expression of ALKBH2 also indicates that it may modulate the responsiveness to Ph-PDT. To confirm a specific function of ALKBH2 in affecting Ph-PDT response, we used a gene-knockdown approach. As illustrated in Figure 3, cytotoxicity of Ph-PDT is enhanced after silencing the ALKBH2 gene. This is the first report to show that the expression of ALKBH2 in glioma cells correlates to Ph-PDT resistance and DNA damage reversal.

The transcription factors involved in the transcription of ALKBH2 remain unknown. However, we have shown increased TP53 binding on the ALKBH2 promoter region, and the levels of TP53 and p-TP53 were rapidly increased after Ph-PDT. Therefore, TP53 appears to be critical in the regulation of ALKBH2 gene expression. There is some evidence that TP53 is involved in PDT, but its exact function in cellular responsiveness is controversial. Mikes et al (2009) reported that TP53-dependent apoptosis affects PDT efficacy. The investigators showed that adenocarcinoma colon cancer cells expressing wild-type TP53 have lower clonogenic efficiency than the TP53-deficient cells after Hypericin-mediated PDT. This may be due to a higher incidence of apoptosis caused by up-regulation of TP53 expression leading to the expression of pro-apoptotic proteins. However, TP53 may also confer PDT resistance to cells, possibly through DNA repair mechanisms, as cells allowed to recover for 24 h had similar clonogenic potential as the TP53-deficient cells. Using another photosensitiser, m-THP, Heinzelmann-Schwarz et al (2003) showed that TP53 is required for apoptosis and interacts with the DNA repair gene Ataxia Telangiectasia Mutated to have a function in apoptosis as well as in responding to DNA damage induced by m-THPC-PDT. Our results are in agreement with these studies and clearly show that TP53 is involved in Ph-PDT. Up-regulation of p-TP53 at Ser-15 is indicative of DNA damage (Maya et al, 2001), thus, DNA repair has an important function in Ph-PDT resistance.

Some in vitro studies on human colon carcinoma, immortalised Li–Fraumeni syndrome and promyelocytic leukaemia found that the cell lines with mutant TP53 have lower sensitivity to Ph-PDT than those with wild-type TP53. This may be due to a decrease in TP53-dependent apoptosis after Ph-PDT (Tong et al, 2000). However, Evans et al (1997) found that Ph-PDT-induced apoptosis was higher in the lymphoblastic cell line with mutant TP53 than that with wild-type TP53, although the cytotoxic effect of Ph-PDT on both cell lines were not different. Another important finding by the same group was that the mutagenicity induced by Ph-PDT in the cell line with mutant TP53 was higher. Therefore, the relationship between TP53 and Ph-PDT responsiveness seems to be cell-type dependent. As different glioma cell lines may possess different TP53 status as well as other genetic differences, the effect of TP53 and ALKBH2 on the efficacy of Ph-PDT should be compared with other cell lines. In our case, the U87 glioma cell line has wild-type TP53 and it may be involved in conferring resistance to these cells against Ph-PDT through the activation of ALKBH2 DNA repair gene. Hence, our findings will further gain knowledge on how to improve the efficacy of Ph-PDT on gliomas by inhibiting the expression of ALKBH2. Further research is required to elucidate the function of TP53 and other regulators in controlling ALKBH2 expression after Ph-PDT.

ACKNOWLEDGEMENTS

The work was in part supported by a Central Research Grant from the Hong Kong Polytechnic University (G.53.56.9051). We thank Axcan Pharma for providing Photofrin for this study and Prof Iris Benzie and Dr Siu Wai Choi for their academic and technical support in the comet assay.

REFERENCES

Adams K, Rainbow AJ, Wilson BC, Singh G (1999) In vivo resistance to photofrin-mediated photodynamic therapy in radiation-induced fibrosarcoma cells resistant to in vitro Photofrin-mediated photodynamic therapy. J Photochem Photobiol B 49: 136–141
TP51 and ALKBH2 in glioma PDT resistance

SY Lee et al

Moan J, Berg K, Kvam E (1990) Effects of photodynamic treatment on DNA and DNA-related cell functions. In Photodynamic Therapy of Neoplastic Disease Kessell D (ed), pp 197–209. CRC Press: Boston

Nowis D, Makowski M, Stoklosa T, Legat M, Issat T, Golab J (2005) Direct tumor damage mechanisms of photodynamic therapy. Acta Biochim Pol 52: 339 – 352

Nyst HJ, Tan IB, Stewart FA, Balm AJ (2009) Is photodynamic therapy a good alternative to surgery and radiotherapy in the treatment of head and neck cancer? Photodiagnosis Photodyn Ther 6: 3 – 11

O’Connor AE, Gallagher WM, Byrne AT (2009) Porphyrin and non-porphyrin photosensitizers in oncology: preclinical and clinical advances in photodynamic therapy. Photochem Photobiol 85: 1053 – 1074

Penning LC, Lagerberg JW, VanDierendonck JH, Cornellsje CJ, Dubbelman TM, VanSteenenvick J (1994) The role of DNA damage and inhibition of poly(ADP-ribosyl)ation in loss of clonogenicity of murine L929 fibroblasts, caused by photodynamically induced oxidative stress. Cancer Res 54: 5561 – 5567

Pervaiz S (2001) Reactive oxygen-dependent production of novel photo-chemotherapeutic agents. FASEB J 15: 612 – 617

Prakash S, Johnson RE, Prakash I (2005) Eukaryotic translesion synthesis DNA polymerases: specificity of structure and function. Annu Rev Biochem 74: 317 – 353

Rigual NR, Tharkappan K, Cooper M, Sullivan MA, Dougherty T, Popat SR, Loore TR, Belf MA, Henderson B (2009) Photodynamic therapy for head and neck dysplasia and cancer. Arch Otolaryngol Head Neck Surg 135: 784 – 788

Ringvoll J, Moen MN, Nordstrand LM, Meira LB, Pang B, Bekkelund A, Dedon PC, Bjaelland S, Samson LD, Falnes PO, Klungland A (2008) AlkB homologue 2-mediated repair of ethenoadenine lesions in mammalian DNA. Cancer Res 68: 4142 – 4149

Saczko J, Chwilikowska A, Kulbacka J, Berdowiska I, Zielinski B, Drag-Zalesinska M, Wysocka T, Lugowski M, Banas T (2008) Photodynamic action in cancer and normal cells induced by the use of porfin in photodynamic therapy. Folia Biol (Praha) 54: 24 – 29

Saczko J, Kulbacka J, Chwilikowska A, Pola A, Lugowski M, Markinckowska A, Malarska A, Banas T (2007a) Cytosolic superoxide dismutase activity after photodynamic therapy, intracellular distribution of Photofrin II and hypericin, and P-glycoprotein localization in human colon adenocarcinoma. Folia Histochem Cytobiol 45: 93 – 98

Saczko J, Mazurkiewicz M, Chwilikowska A, Kulbacka J, Kramer G, Lugowski M, Sniertua M, Banas T (2007b) Intracellular distribution of Photofrin in malignant and normal endothelial cell lines. Folia Biol (Praha) 53: 7 – 12

Styli SS, Howes M, MacGregor L, Rajendra P, Kaye AH (2004) Photodynamic therapy of brain tumours: evaluation of porphyrin uptake versus clinical outcome. J Clin Neurosci 11: 584 – 596

Szabo SE, Monroe SL, Fiorino S, Bitzan J, Loper K (2004) Evaluation of an automated instrument for viability and concentration measurements of cryopreserved hematopoietic cells. Lab Hematol 10: 109 – 111

Tong Z, Singh G, Rainbow AJ (2000) The role of the p53 tumor suppressor in the response of human cells to photofrin-mediated photodynamic therapy. Photochem Photobiol 71: 201 – 210

Usuda J, Hirata T, Ichinose S, Ishizumi T, Inoue T, Ohtani K, Maehara S, Yamada M, Tsutsui H, Okunaka T, Kato H, Ikeda N (2008) Tailor-made approach to photodynamic therapy in the treatment of cancer based on Bcl-2 photodamage. Int J Oncol 33: 689 – 696

Usuda J, Tsunoda Y, Ichinose S, Ishizumi T, Ohtani K, Maehara S, Ono S, Tsutsui H, Ohira T, Okunaka T, Fukukawa K, Sugimoto Y, Kato H, Ikeda N (2010) Breast cancer resistant protein (BCRP) is a molecular determinant of the outcome of photodynamic therapy (PDT) for centrally located early lung cancer. Lung Cancer 67: 198 – 204

Woods JA, Traynor NJ, Brancaleon L, Moseley H (2004) The effect of photofrin on DNA strand breaks and base oxidation in HaCaT keratinocytes: a comet assay study. Photochem Photobiol 79: 105 – 113

Zheng X, Jiang F, Kataokakomi M, Zhang X, Jiang H, Zhang ZG, Chopp M (2008) Sensitization of cerebral tissue in nude mice with photodynamic therapy induces ADAM17/TACE and promotes glioma cell invasion. Cancer Lett 265: 177 – 187